摘要:目的: 比較咪達(dá)普利與培哚普利對原發(fā)性高血壓患者的的降壓效果和不良反應(yīng)。 方法 :將入選的60例1～2級高血壓病患者,隨機分為2組,咪達(dá)普利組,每日晨起口服咪達(dá)普利(5～10 mg,1次/d),培哚普利組,每日晨起口服培哚普利(4～8 mg,1次/d)。治療4周,觀察2組治療前、后的血壓,記錄不良反應(yīng)。 結(jié)果 :經(jīng)治療后咪達(dá)普利與培哚普利組血壓均明顯下降(Plt;0.05),組間差異無統(tǒng)計學(xué)意義(P＞0.05);總不良反應(yīng)發(fā)生率咪達(dá)普利組16.8%,培哚普利組20%,而咪達(dá)普利組的咳嗽發(fā)生率為6.8%,培哚普利組為16.8%。 結(jié)論 :咪達(dá)普利和培哚普利均能有效降壓,二者降壓效果相似,但咪達(dá)普利的咳嗽發(fā)生率較低。Abstract: Objective: To compare the antihypertensive efficacy and safety of imidapril versus peridopril in patients with essential hypertension. Methods : Selected 60 patients with mild to moderate essential hypertension, in which divided two groups by random.They were administered imidapril 5～10 mg once daily or and peridopril 4～8 mg once daily for 4 weeks. During the curative period of 4 weeks, the antihypertensive efficacy and adverse reaction were observed. Results :The blood pressure drecreased prominently in both groups after four weeks treament(Plt;0.05), but there was no significant difference in antihypertensive efficacy between the two groups(P＞0.05). The occurrence of the total adverse reaction in imidapril and peridopril groups was 16.8% and 20%, respectively, while the occurrence of the cough in two groups was 6.8% and 16.8%, respectively. Conclusion :Both imidapril and peridopril exert favourable and similar hepotensive effect, however the cough occurrence of imidapril is lower than that of peridopril.
目的總結(jié)體液中環(huán)狀 RNA 在疾病診斷中作用的研究進展。方法通過閱讀國內(nèi)外關(guān)于體液環(huán)狀 RNA 在疾病診斷方面的相關(guān)文獻，歸納總結(jié)其研究進展。結(jié)果環(huán)狀 RNA 作為內(nèi)源性環(huán)狀 RNA 分子，因其結(jié)構(gòu)穩(wěn)定、序列保守、功能多樣、組織細(xì)胞特異性等特點，被發(fā)現(xiàn)與多種疾病相關(guān)。近來研究發(fā)現(xiàn)，環(huán)狀 RNA 可被分泌至外周血、唾液、尿液、胃液、精漿等體液中，且可穩(wěn)定存在，并與心血管疾病、神經(jīng)系統(tǒng)疾病、自身免疫性疾病、各類惡性腫瘤、代謝性疾病等多種疾病相關(guān)，具有作為疾病非侵入性檢測生物標(biāo)志物之重要潛能。結(jié)論目前研究發(fā)現(xiàn)，體液環(huán)狀 RNA 與多種臨床疾病的診斷相關(guān)，因此對體液環(huán)狀 RNA 與疾病診斷關(guān)系的深入研究有助于開發(fā)臨床疾病非侵入性診斷標(biāo)志物，對于疾病的非侵入性診斷具有重要意義。